tiprankstipranks
Immunome (IMNM)
NASDAQ:IMNM
US Market
Holding IMNM?
Track your performance easily

Immunome (IMNM) Ownership - Who Owns Immunome?

200 Followers

Immunome (IMNM) Ownership Overview

1.73%20.58%39.22%11.43%27.03%
39.22% Other Institutional Investors
11.43% ETFs
27.03% Public Companies and
Individual Investors
The ownership structure of Immunome (IMNM) stock is a mix of institutional, retail, and individual investors. Approximately 71.24% of the company’s stock is owned by Institutional Investors, 1.73% is owned by Insiders, and 27.03% is owned by Public Companies and Individual Investors.
The ownership structure of {name} ({ticker}) stock is a mix of institutional, retail, and individual investors. {displayInstitutionalData, select, display {Approximately {institutionalPercentage} of the company’s stock is owned by Institutional Investors} other {}}{displayInsiderText, select, display {, {insidersPercentage} is owned by Insiders} other {}}{displayInvestorsText, select, display {, and {retailInvestorsPercentage} is owned by Public Companies and Individual Investors.} other {}}

Recent Insider Trading Activity

Date
Name
Activity
Value
Nov 25, 2024
xxxxxxxxxxxxx
$149673
Nov 25, 2024
xxxxxxxxxxxxx
$198030
Nov 25, 2024
Clay Siegall
President & Ceo,director
xxxxxxxxxxxxx
$961807
Sep 20, 2024
xxxxxxxxxxxxx
$230224

Recent Hedge Fund Trading Activity

Date
Firm
Activity
Value
Sep 30, 2024
xxxxxxxxxxxxx
$4105296
Sep 30, 2024
xxxxxxxxxxxxx
$13514611

Top Shareholders

Holder
# of Shares
Type
% Holding
Value
2,933,431Institution4.70%32,707,756
2,359,983Institution3.78%26,313,810
2,177,114Institution3.49%24,274,821
2,041,991Institution3.27%22,768,200
1,504,760Institution2.41%16,778,074
1,127,729Institution1.81%12,574,178
1,024,722Institution1.64%11,425,650
924,392Institution1.48%10,306,971
797,131Institution1.28%8,888,011
726,409Institution1.16%8,099,460

Top Mutual Fund Holders

Holder
# of Shares
Type
% Holding
Value
2,359,983Institution3.78%26,313,810
2,041,991Institution3.27%22,768,200
1,504,760Institution2.41%16,778,074
1,127,729Institution1.81%12,574,178
797,131Institution1.28%8,888,011
726,409Institution1.16%8,099,460
576,868Institution0.92%6,432,078
512,683Institution0.82%5,716,415
448,244Institution0.72%4,997,921
394,182Institution0.63%4,395,129

Top ETF Holders

Holder
# of Shares
Type
% Holding
Value
1,640,351Institution2.63%18,814,826
1,423,396Institution2.28%15,870,865
829,523Institution1.33%9,514,629
926,901Institution1.49%9,102,168
461,777Institution0.74%5,148,814
416,102Institution0.67%4,639,537
233,605Institution0.37%2,679,449
258,598Institution0.41%2,539,432
128,996Institution0.21%1,479,584
118,071Institution0.19%1,316,492

FAQ

Who Owns Immunome (IMNM)?
According to the latest TipRanks data, approximately 39.22% of the company's stock is held by institutional investors, 1.73% is held by insiders, and 27.03% is held by retail investors.
    What percentage of Immunome (IMNM) stock is held by institutional investors?
    According to the latest TipRanks data, approximately 39.22% of Immunome (IMNM) stock is held by institutional investors.
      What percentage of Immunome (IMNM) stock is held by retail investors?
      According to the latest TipRanks data, approximately 27.03% of Immunome (IMNM) stock is held by retail investors.
        Who owns the most shares of Immunome (IMNM)?
        Vanguard owns the most shares of Immunome (IMNM).
          What is the significance of the ownership structure for a publicly traded company?
          The ownership structure can impact the company's decision making, as large institutional investors may exert influence on the company's management and can also affect the company's stock price with their buying and selling patterns.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis